Olvimulogene Nanivacirepvec
Ovarian Serous Adenocarcinoma
Explore 90 assets in Ovarian Serous Adenocarcinoma →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Genelux Corporation
Modality
gene_therapy
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05281471CT.gov Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Serous Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olvimulogene Nanivacirepvec (this asset) | Genelux Corporation | P3 | B · 60 |
| Carboplatin | National Cancer Institute (NCI) | P3 | BBB |
| Letrozole | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | BB |
| Olaparib | Institute of Cancer Research, United Kingdom | P3 | BB |
| Nogitecan | National Cancer Institute (NCI) | P3 | BB |
| Defactinib | Verastem, Inc. | P3 | BB |
| Avutometinib | Verastem, Inc. | P3 | BB |
+42 more in the Ovarian Serous Adenocarcinoma cohort
Other indications for Olvimulogene Nanivacirepvec
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Endometrioid Adenocarcinoma | — | P3 | B · 60 |
| Ovarian Cancer | — | P3 | B · 57 |
| Primary Peritoneal Carcinoma | — | P3 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Olvimulogene Nanivacirepvec in Ovarian Serous Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olvimulogene-nanivacirepvec-ovarian-serous-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →